PROVECTUS BIOPHARMACEUTICALS, INC.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

PVCT$0.04-17.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Deficit

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026

(Unaudited)

Preferred Stock · Preferred Stock · Additional · Accumulated Other · Non-
Series D · Series D-1 · Common Stock · Paid-In · Comprehensive · Accumulated · controlling
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Loss	Deficit	Interest	Total
Balance at January 1, 2026	956,985	$957	14,183,315	$14,183	420,279,879	$420,280	$256,179,846	$(60,191)	$(262,853,812)	$(3,981)	$(6,302,718)
Issuance of common stock of majority-owned subsidiary	-	-	-	-	-	-	66,767	-	-	8,233	75,000
Conversion of 2025 Notes to Series D-1 Preferred Stock	-	-	171,735	172	-	-	491,329	-	-	-	491,501
Stock-based compensation:
Amortization of stock options	-	-	-	-	-	-	306,051	-	-	-	306,051
Comprehensive loss:
Net loss	-	-	-	-	-	-	-	-	(1,290,454)	(10,495)	(1,300,949)
Other comprehensive income	-	-	-	-	-	-	-	285	-	-	285
Balance at March 31, 2026	956,985	957	14,355,050	14,355	420,279,879	420,280	257,043,993	(59,906)	(264,144,266)	(6,243)	(6,730,830)
Conversion of 2025 Notes to Series D-1 Preferred Stock	-	-	203,859	204	-	-	583,230	-	-	-	583,434
Stock-based compensation:
Amortization of stock options	-	-	-	-	-	-	305,944	-	-	-	305,944
Conversion of accrued directors’ fees to Series D-1 Preferred Stock	-	-	189,554	189	-	-	542,312	-	-	-	542,501
Comprehensive loss:
Net loss	-	-	-	-	-	-	-	-	(982,566)	(6,150)	(988,716)
Other comprehensive income	-	-	-	-	-	-	-	103	-	-	103
Balance at June 30, 2026	956,985	$957	14,748,463	$14,748	420,279,879	$420,280	$258,475,479	$(59,803)	$(265,126,832)	$(12,393)	$(6,287,564)

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025

	Accumulated
Preferred Stock · Preferred Stock · Additional · Other · Non-
Series D · Series D-1 · Common Stock · Paid-In · Comprehensive · Accumulated · controlling
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Loss	Deficit	Interest	Total
Balance at January 1, 2025	956,985	$957	13,106,223	$13,106	420,279,879	$420,280	$251,090,027	$(60,741)	$(257,422,961)	$(9,893)	$(5,969,225)
Issuance of common stock of majority-owned subsidiary	-	-	-	-	-	-	634,782	-	-	65,218	700,000
Conversion of 2022 Notes to Series D-1 Preferred Stock	-	-	365,400	365	-	-	1,046,329	-	-	-	1,046,694
Stock-based compensation:
Amortization of stock options	-	-	-	-	-	-	315,100	-	-	-	315,100
Comprehensive loss:
Net loss	-	-	-	-	-	-	-	-	(1,140,108)	(21,494)	(1,161,602)
Other comprehensive income	-	-	-	-	-	-	-	52	-	-	52
Balance at March 31, 2025	956,985	957	13,471,623	13,471	420,279,879	420,280	253,086,238	(60,689)	(258,563,069)	33,831	(5,068,981)
Conversion of 2022 Notes to Series D-1 Preferred Stock	-	-	252,940	253	-	-	723,656	-	-	-	723,909
Stock-based compensation:
Amortization of stock options	-	-	-	-	-	-	322,070	-	-	-	322,070
Comprehensive loss:
Net loss	-	-	-	-	-	-	-	-	(1,814,420)	(37,661)	(1,852,081)
Other comprehensive income	-	-	-	-	-	-	-	328	-	-	328
Balance at June 30, 2025	956,985	$957	13,724,563	$13,724	420,279,879	$420,280	$254,131,964	$(60,361)	$(260,377,489)	$(3,830)	$(5,874,755)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.